Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab versus placebo for HSCT-associated thrombotic microangiopathy
NL-OMON60064Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transplant-associated thrombotic microangiopathy (TA-TMA) comparing Ravulizumab with Placebo (2 arms). Primary endpoint: Event-free survival during the 26-week treatment period. Started Jun 2022; status: completed.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NL-OMON60064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60064.